The Huck Institutes of the Life Sciences

“Metabolomics of sepsis: from metabolic data to clinical diagnosis and mortality prediction”

Dr. Beata Mickiewicz (Bio-NMR-Centre, Department of Biological Sciences, Faculty of Science, University of Calgary, Calgary, AB, Canada)

When: Thursday, September 8, 2016 - 3:00pm - 4:00 pm
Where: Millennium Science Complex, W201
Organizer
Name: Breanne Robinson
Email: bmg14@psu.edu
Phone: 865-1415

Abstract: Despite of an extraordinary development in modern medicine sepsis remains the most life-threating condition in critically ill patients causing millions of deaths around the world. It has been estimated that mortality rate of sepsis is much higher than the mortality rate resulted from HIV/AIDS, prostate cancer and breast cancer combined. Detecting sepsis at an early stage and rapid initiation of appropriate treatment is crucial and can have a significant impact on patient’s outcome. Therefore, it is of high importance to identify new biomarkers and to advance diagnosis and prognosis of sepsis in clinical settings. Systems biology methods have widely been applied in biomarker discovery, clinical diagnosis and outcome prediction. Over the last few decades metabolomics, which aims to identify specific biopatterns (panels of metabolic biomarkers), has significantly expanded its role in the “omics” field. It has already been reported that metabolomics is as a very efficient biochemical tool for clinical diagnosis of various diseased including infectious diseases, osteoarthritis or cancer. Here, the feasibility of metabolomics-based analysis has been explored as a potential approach for septic shock diagnosis and prognosis. The studies were performed on blood samples collected from adults and pediatric patients in intensive care units and emergency departments. The results have shown that metabolite profiling is a promising tool for septic shock diagnosis and prognosis. Additionally, metabolomics approach could be applied for sepsis recognition, its triage and management in clinical settings. A future goal of metabolomics is to establish a simple clinical test that can allow for an early detection of sepsis in order to provide information that can aid in the choice of an optimal patient treatment.